Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting
International Journal of Nanomedicine · 2025
DOI: 10.2147/ijn.s516921 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025. Verfasst von Xiaojuan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, People's Republic of China. Hauptthemen laut MEDLINE: Methotrexate, Folic Acid, Breast Neoplasms, Triterpenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, People's Republic of China.
- Research and Development, Hikma Pharmaceuticals USA Inc., Bedford, OH, USA.
ORCID-Profile: Yu Song
Zitieren
APA
Li, X., Zhang, M., Wang, X., Ma, P., & Song, Y. (2025). Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s516921
Vancouver
Li X, Zhang M, Wang X, Ma P, Song Y. Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting. International Journal of Nanomedicine. 2025. doi:10.2147/ijn.s516921
BibTeX
@article{Li2025,
author = {Li, Xiaojuan and Zhang, Mengxin and Wang, Xiaolin and Ma, Ping and Song, Yu},
title = {Carrier-Free Nanomedicine Based on Celastrol and Methotrexate for Synergistic Treatment of Breast Cancer via Folate Targeting},
journal = {International Journal of Nanomedicine},
year = {2025},
doi = {10.2147/ijn.s516921}
}
EUVIMED